June 20, 2022
The European Medicines Agency (EMA) has initiated its regulatory review for Otsuka Pharmaceutical/Lundbeck’s two-month long-acting injectable version of aripiprazole for the treatment of adults with schizophrenia, the two companies said on June 17. The product is a new formulation provided...read more